Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT01457924 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ofatumumab 3mg
DRUG: Ofatumumab 30mg
DRUG: Ofatumumab 60mg
DRUG: Placebo

Sponsor

GlaxoSmithKline